Patents by Inventor Burke Byrne

Burke Byrne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Liver disease
    Patent number: 12150945
    Abstract: Methods of treating a liver disease or condition, or a symptom thereof, in a subject in need of treatment, are disclosed and described. One method comprises orally administering to a subject, a pharmaceutical composition having an amount of a testosterone, or an ester thereof, sufficient to treat the liver disease or condition, or symptom thereof.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: November 26, 2024
    Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Satish K. Nachaegari, Burke Byrne, Kilyoung Kim, Jonathan A. Baker
  • Liver disease
    Patent number: 12097207
    Abstract: Methods of treating a liver disease or condition, or a symptom thereof, in a subject in need of treatment, are disclosed and described. One method comprises orally administering to a subject, a pharmaceutical composition having an amount of a testosterone, or an ester thereof, sufficient to treat the liver disease or condition, or symptom thereof.
    Type: Grant
    Filed: December 10, 2021
    Date of Patent: September 24, 2024
    Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Satish K. Nachaegari, Burke Byrne, Kilyoung Kim, Jonathan A. Baker
  • Oral (17-ß)-3-Oxoandrost-4-EN-17-YL Tridecanoate Therapy
    Publication number: 20240173334
    Abstract: Disclosed are pharmaceutical compositions and oral dosage forms including capsules containing (17-ß)-3-oxoandrost-4-en-17-yl tridecanoate, and related methods. The capsule fill can include an additive and about 14 wt % to about 42 wt % for androst-4-en-17?-ol-3-one esters that comprise (17-ß)-3-oxoandrost-4-en-17-yl tridecanoate or a combination of (17-ß)-3-oxoandrost-4-en-17-yl undecanoate, (17-ß)-3-oxoandrost-4-en-17-yl dodecanoate, and (17-ß)-3-oxoandrost-4-en-17-yl tridecanoate. A single oral administration to a male subject of one or more dosage forms with a total androst-4-en-17?-ol-3-one equivalent dose of about 150 mg to about 895 mg is provided. In another embodiment, a method for providing a serum concentration of androst-4-en-17?-ol-3-one within a target PK performance for a male subject is provided.
    Type: Application
    Filed: February 9, 2024
    Publication date: May 30, 2024
    Applicant: Lipocine Inc.
    Inventors: Kilyoung Kim, Mahesh V. Patel, Nachiappan Chidambaram, Satish K. Nachaegari, Burke Byrne, Jonathan A. Baker
  • Liver Disease
    Publication number: 20200390785
    Abstract: Methods of treating a liver disease or condition, or a symptom thereof, in a subject in need of treatment, are disclosed and described. One method comprises orally administering to a subject, a pharmaceutical composition having an amount of a testosterone, or an ester thereof, sufficient to treat the liver disease or condition, or symptom thereof.
    Type: Application
    Filed: August 25, 2020
    Publication date: December 17, 2020
    Applicant: Lipocine Inc.
    Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Satish K. Nachaegari, Burke Byrne, Kilyoung Kim, Jonathan A. Baker
  • Liver Disease
    Publication number: 20200383998
    Abstract: Methods of treating a liver disease or condition, or a symptom thereof, in a subject in need of treatment, are disclosed and described. One method comprises orally administering to a subject, a pharmaceutical composition having an amount of a testosterone, or an ester thereof, sufficient to treat the liver disease or condition, or symptom thereof.
    Type: Application
    Filed: August 25, 2020
    Publication date: December 10, 2020
    Applicant: Lipocine Inc.
    Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Satish K. Nachaegari, Burke Byrne, Kilyoung Kim, Jonathan A. Baker
  • LIVER DISEASE
    Publication number: 20200155570
    Abstract: Methods of treating a liver disease or condition, or a symptom thereof, in a subject in need of treatment, are disclosed and described. One method comprises orally administering to a subject, a pharmaceutical composition having an amount of a testosterone, or an ester thereof, sufficient to treat the liver disease or condition, or symptom thereof.
    Type: Application
    Filed: July 19, 2019
    Publication date: May 21, 2020
    Applicant: Lipocine Inc.
    Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Satish K. Nachaegari, Burke Byrne, Kilyoung Kim, Jonathan A. Baker
  • LIVER DISEASE
    Publication number: 20200022991
    Abstract: Methods of treating a liver disease or condition, or a symptom thereof, in a subject in need of treatment, are disclosed and described. One method comprises orally administering to a subject, a pharmaceutical composition having an amount of a testosterone, or an ester thereof, sufficient to treat the liver disease or condition, or symptom thereof.
    Type: Application
    Filed: August 28, 2019
    Publication date: January 23, 2020
    Applicant: Lipocine Inc.
    Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Satish K. Nachaegari, Burke Byrne, Kilyoung Kim, Jonathan A. Baker